Farnie et al. found that the levels of NICD as well as the downstream target Hes1 were increased in all breast ductal carcinoma in situ (DCIS) samples when compared to healthy breast tissues, already at early stages [159]. The gene discussed is HES1; the disease is ductal breast carcinoma in situ.